Tag: Orchestra BioMed

Orchestra BioMed™ Strengthens Operations, R&D and Pharmaceutical Development Expertise with Key Leadership Team Additions

NEW HOPE, Pa., Oct. 10, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing high impact, high value, evidence-based therapeutic solutions for medical procedures that address major medical conditions, announced today that it has appointed three key members to its management team. Joining the […]

Orchestra BioMed™ Adds Three Industry Leaders to Strategic Advisory Board

NEW HOPE, Pa., Oct. 09, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, announced today the appointment of three new members to its Strategic Advisory Board (“SAB”). Joining the Company’s SAB is Gary J. Pruden, former […]

Orchestra BioMed™ Bolsters Leadership Team with Appointment of Inessa Wheeler as Vice President, Strategy and Marketing

NEW HOPE, Pa., Oct. 08, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing high impact, high value, evidence based therapeutic solutions for medical procedures that address major medical conditions, announced today that it has appointed Inessa Wheeler, MBA, as Vice President of Strategy […]

Orchestra BioMed™ Announces Presentation of Positive 2-Year Clinical Results and Program Update for BackBeat® Cardiac Neuromodulation Therapy at TCT 2018

SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing transformational therapeutic devices targeting major medical conditions, presented positive 2-year clinical results from its multicenter clinical trial for BackBeat® Cardiac Neuromodulation Therapy (CNT) at the Transcatheter Cardiovascular Therapeutics (TCT) 2018 in San […]